![]() ![]() In the TB, the RI 50 values for apixaban (154 ug/ml), betrixaban (79 ug/ml), edoxaban (>400 ug/ml) and rivaroxaban (110 ug/ml).Ĭonclusions: Each of the four anti-Xa agents exhibit varying degrees of matrix independent anti-Xa potencies in different systems, the collective order follows edoxaban > apixaban > betrixaban > rivaroxaban. In the AB, the RI 50 values for apixaban (140 ug/ml), betrixaban (46 ug/ml), edoxaban (176 ug/ml) and rivaroxaban (58 ug/ml). ![]() In the BBP, the RI 50 values for apixaban (192 ug/ml), betrixaban (32 ug/ml), edoxaban (152 ug/ml) and rivaroxaban (85 ug/ml). Andexanet alfa produced a concentration dependent reversal of all four anti-Xa agents. Results: Each of the four agents produced varying degrees of inhibition of anti-Xa at 0.062 - 1.0 ug/ml, the IC 50 ranged 0.61 - 1.53 ug/ml in BBP, 0.47 - 1.28 ug/ml in AB and 0.49 - 1.4 ug/ml in TB. The reversibility index (RI 50) of anti-Xa effects by andexanet alfa was determined at 25 - 100 ug/ml. Anti-Xa activities of all four agents were measured in three systems and the reversibility indices of andexanet alfa were profiled. ![]() Apixaban, betrixaban, edoxaban and rivaroxaban were diluted in pH 8.4, 0.5 M tris buffer (TB), blood bank plasma (BBP) and in 5% albuminated buffer (AB) at 0.062 - 1.0 ug/ml. Methods: Andexanet alfa was diluted at 10 mg/ml. Hypothesis: This study aims to compare the relative neutralization of these four anti-Xa agents by andexanet alfa in different matrices. Andexanet alfa may also neutralize the anti-Xa effects of betrixaban and edoxaban. Introduction: Andexanet alfa (Portola Pharmaceuticals, San Francisco, CA) represents a modified factor Xa agent which is approved antidote for apixaban and rivaroxaban.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |